Aficamten is a small-molecule cardiac myosin inhibitor that was compared for the first time in the trial to the standard-of-care beta blocker.

In patients with obstructive hypertrophic cardiomyopathy, the cardiac myosin inhibitor aficamten was superior to the beta-blocker metoprolol for improving symptoms and peak oxygen uptake, according to ...

Cytokinetics' experimental drug improved symptoms such as shortness of breath and chest pain better than a standard-of-care treatment in patients with a type of heart condition, detailed late-stage ...

The US Food and Drug Administration (FDA) is reviewing a New Drug Application (NDA) for Cytokinetics' drug in oHCM with a Prescription Drug User Fee Act (PDUFA) date of 26 December 2025. This ...

MADRID -- The novel oral cardiac myosin inhibitor aficamten improved exercise capacity and symptoms of obstructive hypertrophic cardiomyopathy (HCM) better than standard beta-blocker treatment, the ...

Rejecting the proposal of AstraZeneca Pharma for the update of prescribing information (PI) of Metoprolol Succinate Prolonged Release Tablets I.P. 25, 50, 100 and 200 mg (Seloken ...

Buying metoprolol delivery cost Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue metoprolol succinate extended-release tablet therapy abruptly ...